Keywords
endometrial cancer
metformin
How to Cite
Abstract
Epidemiological evidence for the association between іnsulin resistance and risk of endometrial cancer development has been presented. Cancerogenic effects of factors associated with insulin resistance have been considered and results of studies of metformin – a medication raising tissue sensitivity to insulin, in patients with endometrium hyperplastic processes and endometrial cancer are generalised.References
World Health Organization. Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. – Режим доступа: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
Key T.J. The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk / T.J. Key, M.C. Pike // Br. J. Cancer. – 1988. – Vol. 57, № 2. – Р. 205–212.
Рrospective evaluation of glucose tolerance and insulin resistance among patients with endometrial cancer and atypical endometrial hyperplasia / A. Mitsuhashi, S. Hanawa, N. Yamamoto et al.: 39th ESMO Congress, 26–30 september 2014, Madrid, Spain // Ann. Oncol. (Suppl.4). – 2014. – 928 р.
Prospective evaluation of insulin resistance among endometrial cancer patients / J.K. Burzawa, K.M. Schmeler, P.T. Soliman et al. // Am. J. Obstet. Gynecol. – 2011. – Vol. 204, № 4. – Р. 355.e1–355.e7.
Case-control study of markers of insulin resistance and endometrial cancer risk / C.M. Friedenreich, A.R. Langley, T.P. Speidel et al. // Endocr. Relat. Cancer. – 2012. – Vol. 19, № 6. – Р. 785–792.
Berstein L.M. Insulin resistance, its consequences for the clinical course of the disease, and possibilities of correction in endometrial cancer / L.M. Berstein, J.O. Kvatchevskaya, T.E. Poroshina // J. Cancer Res. Clin. Oncol. – 2004. – Vol. 130, № 11. – Р. 687–693.
A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer / M.J. Gunter, D.R. Hoover, H. Yu et al. // Cancer Epidemiol. Biomarkers Prev. – 2008. – Vol. 17, № 4 – Р. 921–929.
Hyperinsulinemia is associated with endometrial hyperplasia and disordered proliferative endometrium: a prospective cross-sectional study / W. Shan, C. Ning, X. Luo et al. // Gynecol. Oncol. – 2014. – Vol. 132, № 3. – Р. 606–610.
Jenabi E. The effect of body mass index on endometrial cancer: a meta-analysis / E. Jenabi, J. Poorolajal // Public Health. – 2015. – Vol. 129, № 7. – Р. 872–880.
Is diabetes mellitus associated with increased incidence and disease-specific mortality in endometrial cancer? A systematic review and meta-analysis of cohort studies / C. Liao, D. Zhang, C. Mungo et al. // Gynecol. Oncol. – 2014. – Vol. 35, № 1. – Р. 163–171.
Barry J.A. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis / J.A. Barry, M.M. Azizia, P.J. Hardiman // Hum. Reprod. Update. – 2014. – Vol. 20, № 5. – Р. 748–758.
Preliminary investigation of the expression and functions of insulin receptor isoforms in endometrial carcinoma / G. Zhang, X.P. Li, J.L. Wang, L.H. Wei // Zhonghua Fu Chan Ke Za Zhi. – 2012. – Vol. 47, № 11. – P. 839–845.
Overexpression of the insulin receptor isoform A promotes endometrial carcinoma cell growth / C.F. Wang , G. Zhang, L.J. Zhao et al. // PLoS One. – 2013. – Vol. 8, № 8. – Р. e69001.
Ogawa K. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade / K. Ogawa, C. Sun, A. Horii // Oncol. Rep. – 2005. – Vol. 14, № 6. – Р. 1481–1485.
Mitogenic and anti-apoptotic effects of insulin in endometrial cancer are phosphatidylinositol 3-kinase/Akt dependent / Y. Wang, S. Hua, W. Tian et al. // Gynecol Oncol. – 2012. – Vol. 125, № 3. – Р. 734–741.
Extracellular signal-regulated protein kinase activation in endometrium with polycystic ovary syndrome and its significance / X.R. Song, H.Y. Zhang, Y.F. Zhang et al. // Zhonghua Fu Chan Ke Za Zhi. – 2010. – Vol. 45, № 10. – Р. 767–771.
Nahum R. Metabolic regulation of androgen production by human thecal cells in vitro / R. Nahum, K.J. Thong , S.G. Hillier // Hum. Reprod. – 1995. – Vol. 10, № 1. – Р. 75–81.
Fottner C. Regulation of steroidogenesis by insulin-like growth factors (IGFs) in adult human adrenocortical cells: IGF-I and, more potently, IGF-II preferentially enhance androgen biosynthesis through interaction with the IGF-I receptor and IGF-binding proteins / C. Fottner, D. Engelhardt, M.M. Weber // J. Endocrinol. – 1998. – Vol. 158, № 3. – Р.409–417.
Insulin and hyperandrogenism in women with polycystic ovary syndrome / C.G. Baptiste, M.C. Battista, A. Trottier et al. // J. Steroid Biochem. Mol. Biol. – 2010. – Vol. 122, № 1–3. – Р. 42–52.
Kalme Т. Comparative studies on the regulation of insulin-like growth factor-binding protein-1 (IGFBP-1) and sex hormone-binding globulin (SHBG) production by insulin and insulin-like growth factors in human hepatoma cells / T. Kalme, H. Koistinen, M. Loukovaara // J. Steroid Biochem. Mol. Biol. – 2003. – Vol. 86, № 2. – Р. 197–200.
Study on relationship between endogenous androgens and insulin resistance at the different stages of postmenopause / Y.K. Cao, S.F. Zhang, S.E. Zou et al. // Zhonghua Fu Chan Ke Za Zhi. – 2013. – Vol. 48, № 10. – Р. 740–744.
The effect of insulin on aromatase activity in isolated human endometrial glands and stroma / J.F. Randolph Jr., S. Kipersztok, J.W. Ayers et al. // Am. J. Obstet. Gynecol. – 1987. – Vol. 157, № 6. – Р. 1534–1539.
FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer / M. Qiu, W. Bao, J. Wang et al. // BMC Cancer. – 2014. – Vol. 14. – Р. 78.
Особенности гормонально-энергетического обмена у больных с гиперпластическими процессами и раком эндометрия на фоне метаболического синдрома / А.Л. Чернышова, Л.А. Коломиец, Н.В. Юнусова, Е.В. Шаншашвили // Сибирск. онкол. журнал. – 2015. – № 1. – С. 5–12.
Li L. Pathological and immunohistochemical study on estrogen and progesterone receptors in endometrium of polycystic ovarian syndrome / L. Li, C. Yang, J. Qiao // Zhonghua Fu Chan Ke Za Zhi. – 1998. – Vol. 33, № 2. – Р. 89–91.
Lee I.I. Influence of AKT on progesterone action in endometrial diseases / I.I. Lee, J.J. Kim // Biol. Reprod. – 2014. – Vol. 91, № 3. – Article 63.
Huijgens A.N. Factors predicting recurrent endometrial cancer / A.N. Huijgens, H.J. Mertens // Facts Views Vis. Obgyn. – 2013. – Vol. 5, № 3. – Р. 179–186.
Yanase T. Sex hormones and metabolic function / T. Yanase ,
M. Tanabe , T. Nomiyama // Nihon. Rinsho. – 2015. – Vol. 73, № 4. – Р. 571–575.
Suba Z. Interplay between insulin resistance and estrogen deficiency as co-activators in carcinogenesis / Z. Suba // Pathol. Oncol. Res. – 2012. –
Vol. 18, № 2. – Р. 123–133.
Tumor necrosis factor (TNF)-α, soluble TNF receptors and endometrial cancer risk: the EPIC study / L. Dossus, S. Becker, S. Rinaldi et al. // Int. J. Cancer. – 2011. – Vol. 129, № 8. – Р. 2032–2037.
Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study / L. Dossus, S. Rinaldi, S. Becker et al. // Endocr. Relat. Cancer. – 2010. – Vol. 17, № 4. – Р. 1007–1019.
The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma / H.O .Smith, N.D. Stephens, C.R. Qualls et al. // Mol. Oncol. – 2013. – Vol. 7, № 1. – Р. 41–54.
Obesity and the endometrium: adipocyte-secreted proinflammatory TNF-α cytokine enhances the proliferation of human endometrial glandular cells / S. Nair, H. Nguyen, S. Salama, A. Al-Hendy // Obstet. Gynecol. Int. – 2013. – Vol. 2013. – Аrticle 368543.
Interleukin 6 promotes endometrial cancer growth through an autocrine feedback loop involving ERK-NF-κB signaling pathway / Q. Che, B.Y. Liu, F.Y Wang et al. // Biochem. Biophys. Res. Commun. – 2014. – Vol. 446, №1. – Р. 167–172.
Effect of tumor necrosis factor- on estrogen metabolism and endometrial cells: potential physiological and pathological relevance / S.A. Salama, M.W. Kamel, C.R. Diaz-Arrastia et al. // J. Clin. Endocrinol. Metab. – 2009. – Vol. 94, № 1. – Р. 285–293.
Activation of a positive feedback loop involving IL-6 and aromatase promotes intratumoral 17β-estradiol biosynthesis in endometrial carcinoma microenvironment / Q. Che, B.Y. Liu, Y. Liao et al. // Int. J. Cancer. – 2014. –Vol. 135, № 2. – Р. 282–294.
Novel insights in SHBG regulation and clinical implications / R. Simó, C. Sáez-López, A. Barbosa-Desongles et al. // Trends Endocrinol. Metab. – 2015. – Vol. 26, № 7. – Р. 376–383.
Endogenous peptides as risk markers to assess the development of insulin resistance / P. Fang, M. Shi, M. Yu et al. // Peptides. – 2014. – Vol. 51. – Р. 9–14.
Zheng Q. Circulating adiponectin and risk of endometrial cancer / Q. Zheng, H. Wu, J. Cao // PLoS One. – 2015. – Vol. 10, № 6. – Р. e0129824.
Expression of adiponectin receptors and its possible implication in the human endometrium / Y. Takemura, Y. Osuga, T. Yamauchi et al. // Endocrinology. – 2006. – Vol. 147, № 7. – Р. 3203–3210.
Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2 / L. Cong, J. Gasser, J. Zhao et al. // Endocr. Relat. Cancer. – 2007. – Vol. 14, № 3. – Р. 713–720.
Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway / L. Zhang, K. Wen, X. Han et al. // Gynecol. Oncol. – 2015. – Vol. 137, № 2. – Р. 311–320.
Association between serum leptin concentrations and insulin resistance: a population-based study from China / H. Zuo, Z. Shi, B. Yuan et al. // PLoS One. – 2013. – Vol. 8, № 1. – Р. e54615.
High leptin level is an independent risk factor of endometrial cancer: a meta-analysis / P.P. Wang, X.Y. He, R. Wang et al. // Cell Physiol. Biochem. – 2014. – Vol. 34, № 5 – Р. 1477–1484.
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells / J. Gao, J. Tian, Y. Lv et al. // Cancer Sci. – 2009. – Vol. 100, № 3. – Р. 389–395.
Correlation analysis between the expressions of leptin and its receptor (ObR) and clinicopathology in endometrial cancer / Y. Zhang, L. Liu, C. Li, H. Ai // Cancer Biomark. – 2014. – Vol. 14, № 5. – Р. 353–359.
Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways / D. Sharma, N.K. Saxena, P.M. Vertino, F.A. Anania // Endocr. Relat. Cancer. – 2006. – Vol. 13, № 2. – Р. 629–640.
Leptin promotes human endometrial carcinoma cell proliferation by enhancing aromatase (P450arom) expression and estradiol formation / L. Liu, L. Wang, J. Zheng, G. Tang // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2013. – Vol. 170, № 1. – Р. 198–201.
Leptin inhibits the apoptosis of endometrial carcinoma cells through activation of the nuclear factor κB-inducing kinase/IκB kinase pathway / X. Zhou, H. Li, Y. Chai, Z. Liu // Int. J. Gynecol. Cancer. – 2015. – Vol. 25, № 5. – Р. 770–778.
Leptin regulation of proangiogenic molecules in benign and cancerous endometrial cells / C. Carino, A.B. Olawaiye, S. Cherfils et al. // Int. J. Cancer. – 2008. – Vol. 123, № 12. – Р. 2782–2790.
Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1 / L.J. Ma, S.L. Mao, K.L. Taylor et al. // Diabetes. – 2004. – Vol. 53, № 2. – Р. 336–346.
Plasminogen activator inhibitor type 1 (PAI-1) is a valuable biomarker for predicting the metabolic syndrome (MS) in institutionalized elderly residents in Taiwan / Y.Y. Chou, W.H. Sheu, Y.J. Tang et al. // Arch. Gerontol. Geriatr. – 2009. – Vol. 49 (Suppl 2). – Р. S41–S45.
Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer / C. Tecimer, D.L. Doering, L.J. Goldsmith et al. // Gynecol. Oncol. – 2001. – Vol. 80, № 1. – Р. 48–55.
Фактор роста эндотелия сосудов и компоненты системы активации плазминогена при раке и гиперплазии эндометрия / E.C. Герштейн, Е.В. Грицаенко, М.Е. Щербаков и др. // Вопросы онкологии. – 2003. – Т. 49, № 6. – С. 725–729.
Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer / E. Steiner, K. Pollow, D. Hasenclever et al. // Gynecol. Oncol. – 2008. – Vol. 108, № 3. – Р. 569–567.
A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study / S. Dariusz, M. Agnieszka, R. Elzbieta et al. // Eur. J. Obstet. Gynecol. Reprod. Biol. – 2012. – Vol.163, № 2. – Р. 193–199.
Kasznicki J. Metformin in cancer prevention and therapy / J. Kasznicki, A. Sliwinska, J. Drzewoski // Ann. Transl. Med. – 2014. – Vol. 2, № 6. – Р. 57.
Cellular and molecular mechanisms of metformin: an overview / B. Viollet, B. Guigas, N.S. Garcia et al. // Clin. Sci. (Lond). – 2012. – Vol. 122, № 6. – Р. 253–270.
Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway / R.K. Hanna, C. Zhou, K.M. Malloy et al. // Gynecol. Oncol. – 2012. – Vol. 125, № 2. – Р. 458–469.
Another surprise from Metformin: Novel mechanism of action via K-Ras influences endometrial cancer response to therapy / D.A. Iglesias, M.S. Yates, D. van der Hoeven et al. // Mol. Cancer Ther. – 2013. – Vol. 12, № 12. – Р. 2847–2856.
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy / L.A. Cantrell, C. Zhou, A. Mendivil et al. // Gynecol. Oncol. – 2010. – Vol. 116, № 1. – Р. 92–98.
AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer / H. Motoshima, B.J. Goldstein, M. Igata, E. Araki // J. Physiol. – 2006. – Vol. 574 (Pt 1). – Р. 63–71.
Metformin down-regulates endometrial carcinoma cell secretion of IGF-1 and expression of IGF-1R / Y. Zhang, M.X. Li, H. Wang et al. // Asian Pac. J. Cancer Prev. – 2015. – Vol. 16, № 1. – Р. 221–225.
Metformin impairs growth of endometrial cancer cells via cell cycle arrest and concomitant autophagy and apoptosis / A. Takahashi, F. Kimura, A.Yamanaka et al. // Cancer Cell Int. – 2014. – Vol. 14. – Р. 53.
Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase / K.A. Brown, N.I. Hunger, M. Docanto et al. // Breast Cancer Res. Treat. – 2010. – Vol. 123, № 2. – Р. 591–596.
Effects of metformin on the estrogen-induced proliferation and the expression of ER in human endometrial cancer cells / J. Zhang, B. Zhang, Z. Yin et al. // Zhonghua Fu Chan Ke Za Zhi. – 2014. – Vol. 49, № 12. – Р. 932–937.
Does metformin affect ER, PR, IGF-1R, β-catenin and PAX-2 expression in women with diabetes mellitus and endometrial cancer ? / A. Markowska, M. Pawałowska, V. Filas et al. // Diabetol. Metab. Syndr. – 2013. – Vol. 5, № 1. – Р. 76.
Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells / Y. Xie, Y.L. Wang, L. Yu et al. // J. Steroid Biochem. Mol. Biol. – 2011. – Vol. 126, № 3–5. – Р. 1113–1120.
Paradoxic effects of metformin on endothelial cells and angiogenesis /
K. Dallaglio, A. Bruno, A.R. Cantelmo et al. // Carcinogenesis. – 2014. – Vol. 35, № 5. – Р. 1055–1066.
Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells / B.K. Tan, R. Adya, J. Chen et al. // J. Clin. Endocrinol. Metab. –2011. – Vol. 96, № 3. – Р. 808–816.
Metformin reduces endogenous reactive oxygen species and associated DNA damage / C. Algire, O. Moiseeva, X. Deschênes-Simard et al. // Cancer Prev. Res (Phila). – 2012. – Vol. 5, № 4. – Р. 536–543.
Immune-mediated antitumor effect by type 2 diabetes drug, metformin / S. Eikawa, M. Nishida, S. Mizukami et al. // Proc. Natl. Acad. Sci. USA. – 2015. – Vol. 112, № 6. – Р. 1809–1814.
Metformin and the risk of endometrial cancer: a case-control analysis / C. Becker, S.S. Jick, C.R. Meier, M..Bodmer // Gynecol. Oncol. – 2013. – Vol. 129, № 3. – Р. 565–569.
Association between diabetes, diabetes treatment and risk of developing endometrial cancer / J. Luo, S. Beresford, C. Chen et al. // Br. J. Cancer. – 2014. – Vol. 111, № 7. – Р. 1432–1439.
Tseng C.H. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan / C.H. Tseng // Gynecol. Oncol. – 2015. – Vol. 138, № 1. –
Р. 147–153.
Metformin is associated with improved survival in endometrial cancer / E.M. Ko, P. Walter, A. Jackson et al. // Gynecol. Oncol. – 2014. – Vol. 132, № 2. – Р. 438–442.
Metformin use and endometrial cancer survival / N.S. Nevadunsky, A. Van Arsdale, H.D. Strickler et al. // Gynecol. Oncol. – 2014. – Vol. 132, № 1. – Р. 236–240.
Zhang Z.J. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis / Z.J. Zhang, S. Li // Diabetes Obes. Metab. – 2014. – Vol. 16, № 8. – Р. 707–710.
Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer / I. Laskov, L. Drudi, M.C. Beauchamp et al. // Gynecol. Oncol. – 2014. – Vol. 134, № 3. – Р. 607–614.
Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer / K.M. Schuler, B.S. Rambally, M.J. DiFurio et al. // Cancer Med. – 2015. – Vol. 4, № 2. – Р. 161–173.
Effects of metformin on endometrial cancer cell growth in vivo: a preoperative prospective trial / A. Mitsuhashi, T. Kiyokawa, Y. Sato, M. Shozu // Cancer. – 2014. – Vol. 120, № 19. – Р. 2986–2995.
Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent / D.R. Session, K.R. Kalli, I.S. Tummon et al. // Gynecol. Endocrinol. – 2003. –– Vol. 17, № 5. – Р. 405–407.
Shen Z.Q. Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives / Z,Q, Shen, H.T. Zhu, J.F. Lin // Obstet. Gynecol. – 2008. – Vol. 112, № 2 (Pt 2). – Р. 465–467.
Stanosz S. An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women / S. Stanosz // Eur. J. Gynaecol. Oncol. – 2009. – Vol. 30, № 4. – Р. 365–369.
Combination of Diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance / X. Li, J.R. Guo, J.F. Lin et al. // J. Cancer. – 2014. – Vol. 5, № 3. – Р. 173–181.
A phase II study of medroxyprogesterone acetate plus metformin as fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer: ASCO Annual Meeting, 2014 / A. Mitsuhashi, H. Usui, Y. Satoh et al. // J. Clin. Oncol. – Vol. 32, № 15 (Suppl.). – Аbstr. 5592.
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer / H.J. Mackay, E.A. Eisenhauer, S. Kamel-Reid et al. // Cancer. – 2014. – Vol. 120, № 4. – Р. 603–610.
Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression / L. Dong, Q. Zhou, Z. Zhang et al. // J. Obstet. Gynaecol. Res. – 2012. – Vol. 38, № 8. – Р. 1077–1085.